ClinicalTrials.gg

Program

sonelokimab

Also written as “Sonelokimab”, “MSB0010841” and “Sonelokimab (M1095)”.

Its studies are mostly in Hidradenitis Suppurativa · Arthritis, Psoriatic · Psoriasis, led by 3 companies.

Furthest: phase 3, since May 8, 202412 company-led studies, 4 open or runningNext primary completion: Jan 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MoonLake Immunotherapeutics104 open or runningphase 3since May 8, 2024Apr 4, 2022Jan 4, 2027phase 3 · NCT06641089
Bond Avillion 2 Development LP10 open or runningphase 2since Dec 20, 2017Dec 20, 2017none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since May 23, 2014May 23, 2014none ahead

Also a collaborator on its studies: avillion-llp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2014First study: phase 1 study in PsoriasisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02156466 · 41 enrolled · Germany
  2. Dec 20, 2017Bond Avillion 2 Development LP's first study: phase 2 study in PsoriasisNew to Bond Avillion 2 Development LPBond Avillion 2 Development LP · NCT03384745 · 313 enrolled · United States, Bulgaria, Canada and more
  3. Apr 4, 2022MoonLake Immunotherapeutics's first study: phase 2 study in Hidradenitis SuppurativaNew to MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics · NCT05322473 · 234 enrolled · United States, Bulgaria, Canada and more
  4. Nov 28, 2022Phase 2 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT05640245 · 207 enrolled · United States, Bulgaria, Czechia and more
  5. May 8, 20242 phase 3 studies in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT06411899, NCT06411379
  6. Oct 11, 20242 phase 3 studies in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT06641089, NCT06641076
  7. Nov 29, 2024Phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT06768671 · 35 enrolled · United States
  8. May 20, 2025Phase 1 study in Relative BioequivalenceMoonLake Immunotherapeutics · NCT06994936 · 120 enrolled · United Kingdom
  9. May 28, 2025Phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT07007637 · 835 planned · United States, Belgium, Bulgaria and more
  10. Oct 20, 2025Phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT07223138 · 1,560 planned · United States

Ahead

  1. Jan 4, 2027Primary completion: phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT06641089
  2. Feb 4, 2028Primary completion: phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT07223138
  3. Jun 13, 2028Primary completion: phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT07007637

TargetBeta

IL17A →IL17F →read by rule
“Interleukin 17A inhibitor; Interleukin-17F inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
bimekizumabruleUCBphase 343

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07223138Arthritis, Psoriatic · United States3By invitationMoonLake ImmunotherapeuticsFeb 4, 20281,560
NCT07007637Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more3By invitationMoonLake ImmunotherapeuticsJun 13, 2028835
NCT06994936Relative Bioequivalence · United Kingdom1CompletedMoonLake ImmunotherapeuticsNov 1, 2025120
NCT06768671Hidradenitis Suppurativa · United States3CompletedMoonLake ImmunotherapeuticsSep 28, 202635
NCT06641089Arthritis, Psoriatic · United States, Bulgaria, Canada and more3Active, not recruitingMoonLake ImmunotherapeuticsJan 4, 2027600
NCT06641076Arthritis, Psoriatic · United States, Bulgaria, Canada and more3Active, not recruitingMoonLake ImmunotherapeuticsMay 28, 2026960
NCT06411899Hidradenitis Suppurativa · United States, Bulgaria, Canada and more3CompletedMoonLake ImmunotherapeuticsSep 2, 2025422
NCT06411379Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more3CompletedMoonLake ImmunotherapeuticsAug 14, 2025418
NCT05640245Arthritis, Psoriatic · United States, Bulgaria, Czechia and more2CompletedMoonLake ImmunotherapeuticsSep 5, 2023207
NCT05322473Hidradenitis Suppurativa · United States, Bulgaria, Canada and more2CompletedMoonLake ImmunotherapeuticsMay 9, 2023234
NCT03384745Psoriasis · United States, Bulgaria, Canada and more2CompletedBond Avillion 2 Development LPJun 20, 2019313
NCT02156466Psoriasis · Germany1CompletedMerck KGaA, Darmstadt, GermanyAug 201541

How it is read

Names in the registry

  • “Sonelokimab”, 10 entries
  • “MSB0010841”, 4 entries
  • “Sonelokimab (M1095)”, 1 entry
  • “M1095 (Sonelokimab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.